Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment Placebo cohort participants who crossed over to atacicept 150 mg in the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials